caspofungin acetate + Comparator: AmBisome
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Neutropenia
Conditions
Neutropenia, Fever
Trial Timeline
Apr 1, 2004 → Oct 1, 2006
NCT ID
NCT00082537About caspofungin acetate + Comparator: AmBisome
caspofungin acetate + Comparator: AmBisome is a phase 2 stage product being developed by Merck for Neutropenia. The current trial status is completed. This product is registered under clinical trial identifier NCT00082537. Target conditions include Neutropenia, Fever.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00082537 | Phase 2 | Completed |
Competing Products
20 competing products in Neutropenia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Micafungin | Astellas Pharma | Approved | 85 |
| pegfilgrastim | Kyowa Kirin | Phase 2 | 52 |
| HHPG-19K Injection | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Imipenem + Imipenem | Merck | Approved | 85 |
| Posaconazole IV solution + Posaconazole powder for oral suspension | Merck | Phase 1 | 33 |
| Ceftolozane-Tazobactam + Meropenem | Merck | Approved | 85 |
| Ceftolozane-tazobactam IV | Merck | Approved | 85 |
| Daptomycin + Daptomycin | Merck | Phase 3 | 77 |
| pegfilgrastim | Amgen | Phase 3 | 76 |
| Neulasta (pegfilgrastim) | Amgen | Approved | 84 |
| Liposomal amphotericin B (AmBisome®) + Liposomal amphotericin B (AmBisome®) | Gilead Sciences | Approved | 84 |
| Filgrastim Hospira (US) + US-approved Neupogen® | Pfizer | Phase 1 | 32 |
| HSP-130 + US-approved Neulasta + EU-approved Neulasta | Pfizer | Phase 1 | 32 |
| linezolid + vancomycin | Pfizer | Phase 3 | 76 |
| Anidulafungin | Pfizer | Phase 1/2 | 40 |
| Nivestim® | Pfizer | Pre-clinical | 22 |
| Antibacterial agent for the treatment of febrile neutropenia | Pfizer | Pre-clinical | 22 |
| Voriconazole | Pfizer | Phase 1/2 | 40 |
| Filgrastim Hospira (US) + U.S.-approved Neupogen® | Pfizer | Phase 1 | 32 |
| ciprofloxacin + cefepime | Bayer | Phase 3 | 74 |